C-Stem™ technology

Scaling-up cell therapy manufacturing while preserving cell quality

Overcoming cell therapy manufacturing bottlenecks

C-Stem™ is a biomimetic cell culture technology allowing for the mass-production of stem cell- derived therapies with unprecedented cell quality, while cutting manufacturing costs by 10x.

C-Stem technology by TreeFrog Therapeutics

Scale-up

C-Stem™ generates scale-independent cell culture micro-environments, allowing to progress to larger bioreactors without changing key parameters.

Safety

C-Stem perserves genomic integrity and yields mature cell phenotypes,  thereby enhancing the safety of cellular products

Efficacy

C-Stem delivers functional microtissues, which were shown to improve graft integration and reduce time-to-effect.

Step-by-step

The C-Stem™ process

#1 industrial-grade microfluidics

High-throughput stem cell encapsulation

  • Automated encapsulation device
  • Closed, single-use, cGMP compatible process
  • Throughput: > 1,000 capsules per second
C-Stem high throughput stem cell encapsulation
ips cell encapsulation biomimetic 3D stem cell micro-environment
#2 biomimetic 3D micro-environments

Self-organization in in vivo-like stem cell microtissues

  • Epiblast structure promotes fast & high-fidelity cell division
  • Capsule lets nutrients, gas and growth factors in & out
  • Capsule protects cellular content from mechanical stress
#3 Bioreactor scale-up

Exponential stem cell expansion & differentiation in bioreactors

 
  • >100-fold hPSC amplification per week
  • Best-in-class cell viability, pluripotency & genomic integrity
  • Single-batches of over 10 billions cells in 10L bioreactor
  • Differentiation into functional microtissues in bioreactor
ips-derived cell therapy scale-up in bioreactor pluripotent stem cell expansion and differentiation
#4 EASY downstream processing & delivery

Functional 3D microtissues ready for transplantation

  • Capsule removal in minutes to release cell content
  • Mature cell phenotypes enhance product safety & efficacy
  • 3D microtissue format facilitates handling & delivery
PARTNERSHIP MODEL

Our job : to bring the benefits of C-Stem™ as fast as possible to patients through in-house and co-development programs

Adapt 2D to 3D

A 3D stem cell biology team with a dedicated R&D platform adapts existing protocols to C-Stem™ for optimal hPSC amplfication and differentiation

Scale-up early

A bioproduction team develops bioreactor-based manufacturing processes to secure commercial-scale batches for non-clinical and early clinical phases

Enhance delivery

Our scientists bring expertise in logistics, delivery formats and medical devices to maximize the clinical convenience and therapeutic benefits of the product

Optimize manufacturing

Our encapsulation and analytical development teams provide continuous support for the optimization of manufacturing processes

Partner with us

Contact our team !

Pascale Berthet TreeFrog

Pascale Berthet, MSc

CHief Business Development Officer
SEND

C-Stem™ technology: Scaling-up iPS-derived cell therapy manufacturing in bioreactors

TreeFrog Therapeutics has developed C-Stem, a technology allowing for the mass-production of iPS-derived cell therapies in large-scale bioreactors. C-stem is based on a proprietary high-throughput cell encapsulation technology which generates over 1,000 capsules per second. Each stem cell capsule constitutes a biomimetic micro-environment which recapitulates an in-vivo like stem cell niche. In the capsule, pluripotent stem cells self-organize to form an epiblast-like 3D stem cell microtissue which promotes exponential pluripotent stem cell growth, maintenance of homogenous pluripotency and high-fidelity chromosome segregation (preservation of genomic integrity). But the capsule is also protecting stem cells during manufacturing proceses. In fact, C-Stem allows for the scale-independent exponential amplification of hiPSCs and their differentiation into functional 3D microtissues in industrial bioreactors.